Neurona to Present NRTX-1001 Trial Results at AAN Meeting

Neurona Therapeutics, a biotherapeutic firm specializing in regenerative cell therapies for neurological conditions, has announced the presentation of new data from its Phase I/II clinical trial of NRTX-1001 at the upcoming American Academy of Neurology (AAN) Annual Meeting. NRTX-1001 is an experimental cell therapy derived from stem cells, designed to treat drug-resistant mesial temporal lobe epilepsy (MTLE). The therapy involves the use of fully differentiated neural cells, or interneurons, which produce the inhibitory neurotransmitter GABA. These cells are administered as a single dose with the aim of integrating into the brain and reducing seizure activity.
The AAN Annual Meeting, scheduled for April 13-18, 2024, in Denver, will feature the findings in an oral presentation by John Hixson, M.D., Neurona's Senior Medical Director. MTLE is a prevalent form of epilepsy in adults, affecting the temporal lobe and often initiating seizures in the hippocampus. Despite the availability of anti-seizure medications, a significant portion of patients continue to experience seizures, highlighting an unmet medical need.
The clinical trial for NRTX-1001 is an open-label dose-escalation study involving up to 10 patients with drug-resistant MTLE. The trial's initial phase focuses on the safety and potential therapeutic effects of the treatment. Subjects receive a single infusion of NRTX-1001 cells and are then closely monitored. Recruitment for the study is active across various epilepsy centers in the United States, with support from a grant provided by the California Institute for Regenerative Medicine (CIRM).
Neurona Therapeutics is dedicated to creating regenerative cell therapies with the potential for a single-dose cure. Their cell therapy candidates are intended to offer long-lasting repair to impaired neural networks for a range of neurological disorders.